Ignite Creation Date:
2025-12-24 @ 11:47 PM
Ignite Modification Date:
2026-03-10 @ 7:22 PM
Study NCT ID:
NCT03135951
Status:
COMPLETED
Last Update Posted:
2020-11-13
First Post:
2017-04-20
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Pharmacokinetics of SPI-2012 (Eflapegrastim) in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) Chemotherapy
Sponsor:
Spectrum Pharmaceuticals, Inc
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
SPI-GCF-301-PK
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None